Atria Investments Inc Buys 2,041 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Atria Investments Inc lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 60.2% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,429 shares of the medical equipment provider’s stock after acquiring an additional 2,041 shares during the period. Atria Investments Inc’s holdings in Zimmer Biomet were worth $586,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Gradient Investments LLC raised its stake in shares of Zimmer Biomet by 17.3% in the 2nd quarter. Gradient Investments LLC now owns 130,350 shares of the medical equipment provider’s stock valued at $14,147,000 after acquiring an additional 19,224 shares in the last quarter. National Pension Service increased its position in Zimmer Biomet by 3.8% in the 3rd quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock worth $39,893,000 after buying an additional 13,612 shares during the period. CANADA LIFE ASSURANCE Co increased its position in Zimmer Biomet by 7.3% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 229,233 shares of the medical equipment provider’s stock worth $30,265,000 after buying an additional 15,548 shares during the period. Swedbank AB bought a new position in Zimmer Biomet in the 1st quarter worth approximately $2,740,000. Finally, Border to Coast Pensions Partnership Ltd increased its position in Zimmer Biomet by 4.5% in the 3rd quarter. Border to Coast Pensions Partnership Ltd now owns 155,254 shares of the medical equipment provider’s stock worth $16,711,000 after buying an additional 6,623 shares during the period. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Trading Down 1.8 %

NYSE ZBH opened at $110.95 on Wednesday. The stock has a 50-day simple moving average of $106.56 and a 200 day simple moving average of $109.86. The company has a market capitalization of $22.09 billion, a PE ratio of 21.09, a P/E/G ratio of 2.07 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12 month low of $101.47 and a 12 month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.74. The firm had revenue of $1.82 billion during the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.65 earnings per share. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.87%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 18.25%.

Analyst Ratings Changes

Several brokerages have commented on ZBH. UBS Group dropped their price target on Zimmer Biomet from $112.00 to $107.00 and set a “sell” rating on the stock in a research report on Thursday, August 8th. Robert W. Baird decreased their price objective on Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a report on Thursday, August 8th. Evercore ISI decreased their price objective on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. JPMorgan Chase & Co. decreased their price objective on Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a report on Monday, September 16th. Finally, Truist Financial lifted their price objective on Zimmer Biomet from $112.00 to $117.00 and gave the stock a “hold” rating in a report on Friday, November 1st. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.